Health

Late-Stage Study of Single-Dose Vaccine Starts in U.S.

Pharmaceutical giant Johnson & Johnson began Wednesday a large final study to prove if a single-shot coronavirus vaccine can protect against the disease.

The study will be among the world’s largest vaccine studies thus far, with testing taking place among 60,000 people in the U.S., South Africa, Argentina, Brazil, Chile, Colombia and Peru, The Associated Press reported.

Some vaccines, such as those in the manufacturing process by U.S. companies Moderna and Pfizer in addition to those throughout the world, are in the final testing stages. While hope exists among experts a viable vaccine will be ready for use by the end of the year, U.S. health officials emphasize the race for a vaccine hasn’t cut corners.

“We want to do everything we can without sacrificing safety or efficacy — we’re not going to do that — to make sure that we end up with vaccines that are going to save lives,” said Dr. Francis Collins, director of the National Institutes of Health, AP reported.

Tags
Show More

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *


By submitting this form, you are consenting to receive marketing emails from: Washington Informer Newspaper, 3117 Martin Luther King Jr. Ave SE, Washington, DC, 20032, http://www.washingtoninformer.com. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact

Back to top button

My News Matters to me - Washington Informer Donations

Be a Part of The Washington Informer Legacy

A donation of your choice empowers our journalists to continue the work to better inform, educate and empower you through technology and resources that you use.

Click Here Today to Support Black Press and be a part of the Legacy!

Subscribe today for free and be the first to have news and information delivered directly to your inbox.

Select list(s) to subscribe to


By submitting this form, you are consenting to receive marketing emails from: Washington Informer Newspaper, 3117 Martin Luther King Jr. Ave SE, Washington, DC, 20032, http://www.washingtoninformer.com. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact
Close

Adblock Detected

Please consider supporting us by disabling your ad blocker